Another Immuno-Oncology Company, Another $90+ Million IPO

February 4, 2019

Harpoon Therapeutics announced that it will raise up to $93 million in its IPO. The company is offering 5,400,000 shares and is granting underwriters the option to purchase up to an additional 810,000 shares. The shares expected offering price is $13 to $15. Harpoon has applied to list our common stock on the Nasdaq Global Select Market under the trading symbol “HARP.”

Harpoon is developing a novel class of T cell therapeutics that aims to achieve superior efficacy in penetrating solid tumors as an “off-the-shelf” T cell therapy. The company currently has four candidates in development.

Its most advanced candidate in terms of development is HPN424. HPN424 is in Ph I trials and is for treating prostate cancer. Preliminary results from the Ph I trial indicated that the drug was activating T-cells and that it was well tolerated in terms of toxicity.

In November of 2018, the company raised $70 million in a series C round. The company entered into a research collaboration agreement with Abbvie in 2017.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.